Uterine corpus epithelioid leiomyosarcoma

Summary

Uterine corpus epithelioid leiomyosarcoma (MONDO:0003782) is a disease. A subtype of epithelioid leiomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	uterine corpus epithelioid leiomyosarcoma
Mondo ID	MONDO:0003782
DOID	DOID:6139
NCIT	C40174
UMLS	C1519851
MedGen	274363
GARD	0023667
Anatomy (UBERON)	UBERON:0009853
Is cancer (heuristic)	no

Also known as: body of uterus epithelioid leiomyosarcoma · epithelioid leiomyosarcoma of body of uterus · uterine corpus epithelioid leiomyosarcoma · uterine epithelioid leiomyosarcoma

Disease family

This is a subtype of epithelioid leiomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › musculoskeletal system disorder › musculoskeletal system cancer › muscle cancer › smooth muscle cancer › leiomyosarcoma › epithelioid leiomyosarcoma › uterine corpus epithelioid leiomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.